73
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer

, , , , , , & show all
Pages 3275-3283 | Published online: 24 Apr 2019

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR. Role of pemetrexed in non-small cell lung cancer. Cancer Invest. 2007;25(1):59–66. doi:10.1080/0735790060113074817364559
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
  • Ogawa H, Shionyu M, Sugiura N, et al. Chondroitin sulfate synthase-2/chondroitin polymerizing factor has two variants with distinct function. J Biol Chem. 2010;285(44):34155–34167. doi:10.1074/jbc.M110.10955320729547
  • Kitagawa H, Izumikawa T, Uyama T, Sugahara K. Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization. J Biol Chem. 2003;278(26):23666–23671. doi:10.1074/jbc.M30249320012716890
  • Filipek-Górniok B, Holmborn K, Haitina T, et al. Expression of chondroitin/dermatan sulfate glycosyltransferases during early zebrafish development. Dev Dyn. 2013;242(8):964–975. doi:10.1002/dvdy.2398123703795
  • Kalathas D, Theocharis DA, Bounias D, et al. Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Rep. 2011;4(2):363–368. doi:10.3892/mmr.2011.43121468578
  • Fan YH, Xiao B, Lv SG, Ye MH, Zhu XG, Wu MJ. Lentivirus-mediated knockdown of chondroitin polymerizing factor inhibits glioma cell growth in vitro. Oncol Rep. 2017;38(2):1149–1155. doi:10.3892/or.2017.573128627702
  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi:10.1038/358889486653
  • Krueger U, Bergauer T, Kaufmann B, et al. Insights into effective RNAi gained from large-scale siRNA validation screening. Oligonucleotides. 2007;17(2):237–250. doi:10.1089/oli.2006.006517638527
  • Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. Nat Methods. 2006;3(9):701–706. doi:10.1038/nmeth92116929315
  • Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203. doi:10.1016/j.cell.2007.11.02518083107
  • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature0594517625570
  • Liu S, Yang H, Jiang Y, Zhang T, Yan R, Zhang J. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. Future Med Chem. 2018;10(14):1705–1720. doi:10.4155/fmc-2018-003329961337
  • Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126(2):231–235. doi:10.1016/j.cell.2006.07.00716873051